Negara: Kanada
Bahasa: Inggris
Sumber: Health Canada
AMYLASE; PROTEASE; LIPASE
VIVUS LLC.
A09AA02
MULTIENZYMES (LIPASE, PROTEASE ETC)
43750UNIT; 25000UNIT; 10500UNIT
CAPSULE (DELAYED RELEASE)
AMYLASE 43750UNIT; PROTEASE 25000UNIT; LIPASE 10500UNIT
ORAL
100
Prescription
DIGESTANTS
Active ingredient group (AIG) number: 0302964029; AHFS:
APPROVED
1999-05-03
_Pancrease MT (pancrelipase) _ _Page 1 of 18_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR PANCREASE® MT 2 2,600 USP UNITS LIPASE/10,850 USP UNITS AMYLASE/6,200 USP UNITS PROTEASE /ORAL CAPSULE PR PANCREASE® MT 4 4,200 USP UNITS LIPASE/17,500 USP UNITS AMYLASE/10,000 USP UNITS PROTEASE/ORAL CAPSULE PR PANCREASE® MT 10 10,500 USP UNITS LIPASE/43,750 USP UNITS AMYLASE/25,000 USP UNITS PROTEASE /ORAL CAPSULE PR PANCREASE® MT 16 16,800 USP UNITS LIPASE/70,000 USP UNITS AMYLASE/40,000 USP UNITS PROTEASE /ORAL CAPSULE PR PANCREASE® MT 20 21,000 USP UNITS LIPASE/61,000 USP UNITS AMYLASE/37,000 USP UNITS PROTEASE /ORAL CAPSULE Pancrelipase Delayed-Release Capsules Digestant Vivus LLC 900 East Hamilton Avenue, Suite #550, Campbell, California, USA 95008 Date of Initial Authorization: December 31, 1988 Date of Revision: September 5, 2023 Submission Control Number: 273267 _ _ _Pancrease MT (pancrelipase) _ _Page 2 of 18_ RECENT MAJOR LABEL CHANGES TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES .......................................................................................... 2 TABLE OF CONTENTS ............................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1 INDICATIONS ............................................................................................................. 4 1.1 Pediatrics .................................................................................................................. 4 1.2 Geriatrics .................................................................................................................. 4 2 CONTRAINDICATIONS ................................................................................................ 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ........................................................ Baca dokumen lengkapnya